Summary The EVI-I gene was originally detected as an ectopic viral insertion site and encodes a nuclear zinc finger DNA-binding protein. Previous studies showed restricted EVI-1 RNA or protein expression during ontogeny; in a kidney and an edometrial carcinoma cell line; and in normal murine oocytes and kidney cells. EVI-1 expression was also detected in a subset of acute myeloid leukaemias (AMLs) and myelodysplasia. Because EVI-1 is expressed in the urogenital tract during development, we examined ovarian cancers and normal ovaries for EVI-1 RNA expression using reverse transcription-polymerase chain reaction (RT-PCR) and RNAase protection. Chromosome abnormalities were examined using karyotypes and whole chromosome 3 and 3q26 fluorescence in situ hybridisation (FISH). RNA from six primary ovarian tumours, five normal ovaries and 47 tumour cell lines (25 ovarian, seven melanoma, three prostate, seven breast and one each of bladder, endometrial, lung, epidermoid and histiocytic lymphoma) was studied. Five of six primary ovarian tumours, three of five normal ovaries and 22 of 25 ovarian cell lines expressed EVI-1 RNA. A variety of other non-haematological cancers also expressed EVI-1 RNA. Immunostaining of ovarian cancer cell lines revealed nuclear EVI-1 protein. In contrast, normal ovary stained primarily within oocytes and faintly in stroma. Primary ovarian tumours showed nuclear and intense, diffuse cytoplasmic staining. Quantitation of EVI-1 RNA, performed using RNAase protection, showed ovarian carcinoma cells expressed 0 to 40 times the EVI-I RNA in normal ovary, and 0 -6 times the levels in leukaemia cell lines. Southern analyses of ovarian carcinoma cell lines showed no amplification or rearrangements involving EVI-1. In some acute leukaemias, activation of EVI-1 transcription is associated with translocations involving 3q26, the site of the EVI-I gene. Ovarian carcinoma karyotypes showed one line with quadruplication 3(q24q27), but no other clonal structural rearrangements involving 3q26. However, whole chromsome 3 and 3q26 FISH performed on lines with high EVI-1 expression showed translocations involving chromosome 3q26. EVI-1 is overexpressed in ovarian cancer compared with normal ovaries, suggesting a role for EVI-1 in solid tumour carcinogenesis or progression. Mechanisms underlying EVI-1 overexpression remain unclear, but may include rearrangements involving chromosome 3q26.
Ovarian cancer is the leading cause of death from female genitourinary cancers in the United States (Boring et al., 1994) . Compared with other solid tumours, relatively little is known regarding the molecular pathogenesis and progression of ovarian cancers. Mutations and/or altered expression of p53 (Marks et al., 1991; Milner et al., 1993) and HER-2/neu (Rubin et al., 1993 (Rubin et al., , 1994 occur frequently, but ras mutations are relatively infrequent (van't Veer et al., 1988; Smith et al., 1989) compared with other solid tumours. Sporadic reports of abnormal expression of other proto-oncogenes, including myc, fos, AKT2 and int-2 have appeared (Sasano et al., 1990; Cheng et al., 1992) , but the roles of these genes in ovarian carcinogenesis and the relative frequencies of their expression in ovarian cancers remain unclear.
The EVI-I (ecotropic virus integration-1) gene was originally detected as a murine virus insertion site in experimental leukaemias (Mucenski et al., 1988) and localised to human chromosome band 3q26 (Morishita et al., 1990a) . The gene encodes a nuclear zinc finger protein with specific DNA-binding properties (Matsugi et al., 1990; Perkins et al., 1991a; Delwel et al., 1993) . The function of EVI-I in normal cells remains unknown, but it is sequentially expressed in limb buds during ontogeny, suggesting a role in cell migration (Perkins et al., 1991b) . During embryological development in mice, EVI-1 protein is expressed at high levels in restricted sites including the urinary and Mullerian systems, bronchial epithelium, focal areas in nasal cavities, endocardial cushions, and developing limbs (Perkins et al., 1991b) . Recent data suggest EVI-l alters transcription directed by other Zn finger genes, such as GATA-l (Kreider et al., 1993) and regulates c-fos expression (Tanaka et al., 1994) , thus controlling gene expression.
In normal adult murine tissues, EVI-1 expression was previously detected in murine kidney tubules and oocytes (Perkins et al., 199 ib; Morishita et al., 1990c) . The presence of EVI-l protein has also been demonstrated in human kidney and endometrial tissues and EVI-l RNA was induced in short-term culture of kidney tubule cells by cAMP (Bartholomew and Clark, 1994) . Using Northern analysis, expression of EVI-1 RNA was detected in only a few human solid tumour cell lines (Morishita et al., 1990b) .
Because EVI-1 is expressed in developing urogenital tract and normal oocytes, we examined its expression in normal human ovary and ovarian cancers. Using reverse transcription -polymerase chain reaction (RT -PCR), EVI-1 RNA was detected in the vast majority of ovarian cancers and in many other solid tumours. Some ovarian tumours expressed extremely high levels of EVI-l RNA compared with normal ovary, suggesting that the EVI-I gene may play a role in pathogenesis or progression of ovarian cancers.
Methods

Tumour specimens
Primary ovarian cancer tissue specimens were obtained from untreated patients (Thompson et al., 1994) . All specimens, including those used to establish cell lines from tumours, were obtained as excess pathological material using procedures approved by the Committee on Human Subjects, University of Arizona. Primary tumours and normal ovaries were stored frozen at -70°C until used. Four of five normal ovaries studied contained both oocytes and stromal elements. The fifth, obtained from a post-menopausal patient, contained no oocytes. Previously established cancer cell lines were maintained using RPMI-1640 medium with either 5% or 10% fetal bovine serum (FBS), except the HECIb endometrial carcinoma (Morishita et al., 1990b) line, which was maintained in minimum essential median (MEM) with 10% FBS. These lines included: OVCAR3 (Cheng et al., 1992) , SKOV3 (Buick et al., 1985 ), 2008 (Naredi et al., 1994 , 2780 (Mann et al., 1991) , 367 and Colo-316 (Woods et al., 1979) . Ovarian carcinoma cell lines established from primary tumours were designated UACC (numbers 469, 1598, 326, 188, 591, 1763, 2614, 1703, 2996, 2983, 2727, 295, 1499, 2980, 1123, 2982, 341, 2912 and 2661) and characterised and maintained as previously described (Leibowitz, 1986) . Melanoma cell lines developed from primary tumours were also assigned UACC numbers (475, 502 and 2946) . In addition, three previously described melanoma lines, 355, 242 and 289 were tested. With the exception of MDA 468 (Taetle et al., 1988) , all breast tumour cell lines were developed at the University of Arizona, and included UACC numbers 2642, 2715, 2436, 245, 812 and 893. All UACC cell lines were established from primary tumour tissue and the original diagnosis confirmed by independent pathology review. Factor-dependent UCSD/AML1 and factor-independent HEL leukaemia cells expressing EVI-1 RNA were maintained as described previously (Russell et al., 1993 (Russell et al., , 1994 Oval et al., 1990 (Morishita et al., 1990b) . The 3' EVI-1 reverse PCR yields two characteristic products of 254 and 272 bases owing to alternative splicing (Russell et al., 1994) . Histone or GAPDH (available for later experiments) RNA was assessed in parallel to assure RNA integrity (Russell et al., 1994) .
Identity of EVI-1 PCR products was verified by probing Southern blots of RT-PCR products with an oligonucleotide internal to the priming sequences (Russell et al., 1993) . Both 3' EVI-I PCR products from two cell lines, Colo316 and SKOV-3, were also sequenced using automated techniques (Scripps Clinic and Research Foundation, La Jolla, CA, USA), and yielded the expected EVI-1 sequences (Morishita et al., 1990b RNA levels were also assessed by Northern analyses or slot blots as previously described . Total cell RNA was extracted as described above and Northern or slot blots probed with a PCR-generated 272 bp probe, corresponding to the RNAase protection assay. Blots were normalised for RNA loading using a ,B-actin probe Taetle et al., 1991) . RNA half-lives were estimated by culturing cells with 10 jug ml-' actinomycin-D for 2 and 4 h as described . Responses to 10 ug/ml cycloheximide were assessed in a similar fashion.
Southern blot analysis DNA prepared from normal donor lymphocytes, UCSD/ AML1 cells , and carcinoma cell lines OVCAR3, SKOV-3, 2780 , 2008 , UACC 1598 and UACC 295 was digested with EcoRI, BamHI or both enzymes and electrophoresed in 0.9% agarose gels. DNA products were transfered to nylon filters as previously described (Taetle et al., 1991) and hybridised with a PCRgenerated, digoxinin-labelled probe to EVI-1 5' flanking sequences from -486 to -974 base pairs (Madden et al., 1991) ; a 2.0 kb probe containing human 5' flanking and coding sequences (Morishita et al., 1990b) ; and a full-length, murine EVI-1 cDNA . Blots were stripped and probed for actin to ensure DNA integrity. EVI-I DNA content was expressed relative to normal ovary or lymphocyte DNA probed on the same blot.
Karyotypes and fluoroscence in situ hybridisation (FISH) Cell line karyotypes were performed as described (Thompson et al., 1994) . Whole chromosome 3 FISH was performed according to manufacturer's instructions (Oncor, Gaithersburg, MD, USA) (Pinkel et al., 1988) . A human 3q26, bandspecific probe was created by microdissection of normal chromosome 3 and labelled as previously described Thompson et al., 1995) . Hybridisation and FISH were performed as described previously Thompson et al., 1995) .
Results
Previous studies using Northern anlayses suggested EVI-1 RNA expression was highly restricted among established human, non-haematological, tumour cell lines (Morishita et al., 1990b) . In contrast, using RT-PCR, EVI-I RNA products of 254 and 272 bp (because of alternate splicing) were detected in five of six established ovarian cancer cell lines. Cell line 2780 was consistently negative using RT-PCR direct at both 5' (not shown) and 3' EVI-1 coding sequences (Figure la) , indicating truncated EVI-I transcripts were not present. This result for 2780 cells was also verified using immunostaining and RNAase protection (see below). EVI-I RNA expression was previously induced in primary kidney cells by cAMP (Bartholomew and Clark, 1994) and acute promyelocytic leukaemia cells by all-trans retinoic acid . However, cAMP (10-7 or 10-6 M) alltrans retinoic acid (10-6 or 10-7 M) failed to induce EVI-1 RNA expression detected by RT-PCR in 2780 ovarian carcinoma cells. Similarly, 17 of 19 ovarian lines established within the Arizona Cancer Center and tested at passages < 20 also expressed EVI-I RNA (for example, Figure lb) . All cell lines positive for 3' EVI-1 PCR products were also positive using 5' product primers. The latter encompass the major start site and first 434 bp of the coding sequence. Thus all cells positive for EVI-I RNA appeared to contain full-length transcripts.
Frozen primary tumour specimens (six ovarian epithelial and one ovarian sarcoma) were also positive for EVI-1 RNA using RT-PCR (Table I) . Four of four ovaries obtained from premenopausal patients, which were histologically normal except for the presence of follicular cysts, contained low but detectable levels of EVI-1 RNA. RT-PCR of a normal post-menopausal (oocyte-poor) ovary did not contain EVI-I RNA. RT-PCR was also used to assess EVI-I expression in non-ovarian tumour cells and normal fibroblasts and was detected in the majority of these cells ( (Figure 2a) . In contrast, immunostaining of primary ovarian carcinomas was intense in cytoplasm and present in nuclei (Figure 2b presence of actinomycin-D was 2.5 h, a value nearly identical to those previously obtained for EVI-I transcripts in UCSD/ AML1 leukaemia and HEC-IB endometrial carcinoma cells . Levels of EVI-I RNA 146-153% of control after exposure to 10 ,ug ml-' cycloheximide for 2 h (two studies). Southern blots did not detect rearrangements or amplification of EVI-l in ovarian carcinoma cell lines (Table II) . In contrast, a rearrangement predicted from pulse-field maps Karyotypes and modes were determined as described previously (Thompson et al., 1994) . FISH was performed using a whole chromosome 3 paint or 3q26 band-specific probe. EVI-I DNA was determined from Southern blots probed for multiple areas of the EVI-I gene. Results represent means of four experiments normalised to either normal ovary or lymphocyte DNA. EVI-1 RNA levels are expressed relative to normal ovary EVI-1 RNA content using RNAase protection (See Methods). ND, not done.
UACC 1598 carcinoma DNA probed with a full-length EVI-1 cDNA also showed no rearrangements or deletions, indicating that failure of these cells to express EVI-I was not due to bi-allelic gene deletion.
In leukaemia cells, abnormal EVI-1 transcription is frequently accompanied by rearrangements involving chromosome 3q26, the site of the EVI-I gene (Warrel et al., 1983; Morishita et al., 1992; Oval et al., 1992) . Karyotypes, whole chromosome 3 and 3q26 band-specific FISH were performed in nine ovarian cell lines (Table II) . UCSD/AML-1 leukaemia cells known to contain t(3;3)(q21-26) were used as controls (Figure 4a ). OVCAR-3 cells contained a [der(3)] [quadruplication(3)(q24-27)] in addition to two normal chromosome 3s. Whole chromosome 3 and 3q26 FISH confirmed that [der(3)] material was of chromosome 3 origin ( Figure  4c ). Other cell lines did not have karyotype abnormalities involving 3q26, but chromosome 3 and 3q26 FISH showed der(3) chromosomes in SKOV-3 (Figure 4b ) and Colo-316 cells, which were not detected by karyotype (Table II) . These findings suggest chromosome 3q26 rearrangements are involved in EVI-1 overexpression in these cells.
Discussion
EVI-1 is a member of a large family of zinc finger, DNAbinding proteins (Schleif, 1988; O'Halloran, 1993) . These genes are extremely common, and constitute up to 1% of some human chromosomes (O'Halloran, 1993) . While some zinc finger genes are clearly transcription factors (e.g. retinoic acid receptors; Muscenski et al., 1988) or function as tumoursuppressors (e.g. WTI ; Madden et al., 1991; Gessler et al., 1990) , the functions of many members of this gene family remain unknown.
Expression of EVI-1 was previously documented only in HECIb endometrial carcinoma cells from which the human cDNA was cloned (Morishita et al., 1990b) . Using RT-PCR, EVI-1 RNA was not detected in normal blood or marrow mononuclear cells, but is expressed by acute myelogenous leukaemia blasts and cells from the marrow of myelodysplasia patients (Russell et al., 1994; Morishita et al., 1992; Oval et al., 1992) . Enforced EVI-l expression in blood cells antagonises transcriptional regulation by the erythroid/ megakaryocytic-specific GATA-I protein and blocks erythropoietin-stimulated growth and in vitro red blood cell differentiation . A fusion gene containing full-length EVI-l and generated by t(3;21) in AML also blocks haemopoietic cell line differentiation (Tanaka et al., 1995) . Recent studies suggest EVI-I and EVI-1 fusion genes control c-fos transcription and that consensus EVI-1 binding sequences can act as transcriptional regulators (Tanaka et al., 1994; Morishita et al., 1995) . These studies indicate EVI-1 controls or modifies expression of important genes in human cancers, and can control cell differentiation.
In contrast to previous studies using Northern analyses (Morishita et al., 1990b) , the present studies using RT-PCR and RNAase protection indicate EVI-I RNA expression is common in human solid tumours. The RT-PCR assay was previously shown to be 300 times more sensitive than RNAase protection and was able to detect one positive luekaemia cell diluted in 1000 in normal marrow cells (Russell et al., 1994) . Thus, techniques used in the present studies are at least 3 logs more sensitive than those used in previous studies of human solid tumours (Morishita et al., 1990b Figure 4 Fluorescence in situ hybridisation (FISH) with a chromosome 3q26 probe generated using microdissection. (a) UCSD/AML1 leukaemia cells containing known t(3;3)(q21;q26). The probe detects previously demonstrated translocated 3q26 sequences containing EVI-1 (arrow) (Morishita et al., 1992; Oval et al., 1992) . (b) SKOV-3 ovarian carcinoma cells with high EVI-l RNA levels demonstrating multiple derivative chromosomes containing 3q26 sequences. Chromosomes shown by arrows were demonstrated to be abnormal der(3) by whole chromosome FISH and Giemsa prebanding. (c) OVCAR3 ovarian carcinoma cells demonstrating inversion/duplication of 3q26 sequences (arrows). protection assays indicate high-level EVI-l expression in ovarian carcinoma and other solid tumour cell lines compared with normal ovary, suggesting EVI-l plays a role in ovarian tumour progression or pathogenesis. Southern analyses (Table II) indicate EVI-1 overexpression was not accompanied by EVI-l gene amplification.
In leukaemia cells, EVI-l transcription is activated by long-range translocations involving chromosome 3q26 segments 3' or 5' of the EVI-1 gene (Russell et al., 1993; Morishita et al., 1992) . It is unclear over what distances chromosome 3 rearrangements can alter EVI-I transcription, but one case of leukaemia with EVI-I expression with a 3q26 rearrangement was mapped by pulse-field gels up to 900 kb 5' and 3' of the gene without detecting a rearrangement (Jagasia et al., 1994) . Although further studies are required to delineate mechanisms controlling EVI-1 expression in ovarian carcinoma cells, the half-life of EVI-I RNA was identical to values in acute leukaemia and endometrial carcinoma cells . Despite this finding, Southern analyses did not show EVI-I amplification or rearrangements (Table II) . These findings suggest EVI-I expression is also regulated by transcription in ovarian cancer cells. Although only one ovarian carcinoma cell line with increased EVI-I RNA showed a definite karyotype abnormality involving band 3q26, using FISH, lines with relative EVI-I overexpression showed rearrangements using a 3q26 band-specific probe. These studies suggest that rearrangements involving 3q26 are involved in abnormal EVI-1 expression in non-haemopoietic tumours as well.
The role and regulation of EVI-1 in non-haematological tissues are unknown. Sequential expression of EVI-I in ontogeny suggests a role in cell migration or adhesion (Perkins et al., 1991b) . EVI-I is also highly conserved among species and recent studies in nematodes indicate it is highly homologous to a zinc finger binding protein, egl-43, important in long-range migration of (hermaphroditespecific) motor neurons (Garriga et al., 1993) . Further studies investigating potential role(s) of EVI-I by gene transfer in ovarian tumours are in progress.
